Clicky

Surface Oncology, Inc.(SURF)

Description: Surface Oncology is a clinical-stage immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD47 and CD73. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response, alone or in combination with other therapies. The company has a pipeline of immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies.


Keywords: Medicine Clinical Medicine Tumor Immunotherapy Cancer Treatment Cancer Immunotherapy Immunotherapies Virotherapy Novel Cancer Cancer Research Active Immunotherapy CD47 Cd73 Tumor Microenvironment

Home Page: www.surfaceoncology.com

SURF Technical Analysis

50 Hampshire Street
Cambridge, MA 02139
United States
Phone: 617 714 4096


Officers

Name Title
Dr. Robert W. Ross M.D. Pres, CEO & Director
Dr. Vito J. Palombella Ph.D. Chief Scientific Officer
Dr. Alison O'Neill M.D. Chief Medical Officer
Ms. Jessica Fees CPA CFO & Treasurer
Ms. Chandra Adams J.D. VP of Legal & Intellectual Property, Dep. Gen. Counsel and Corp. Sec.
Ms. Lisa McGrath Chief People Officer
Mr. Henry C. Rath Chief Bus. Officer
Ms. Shannon Rourke Devens Sr. VP of Devel. Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4724
Price-to-Sales TTM: 1.6001
IPO Date: 2018-04-19
Fiscal Year End: December
Full Time Employees: 67
Back to stocks